Q-omics provides the consensus-scored PGLYRP4 profile across patient tissues and cancer cell-line models. PGLYRP4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PGLYRP4 is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, PGLYRP4 RNA expression shows 11,532 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BRCA, LUSC, and ESCA as cancer lineages where PGLYRP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGLYRP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGLYRP4 survival associations across molecular data types. PGLYRP4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGLYRP4 RNA expression–survival associations across cancer types. High PGLYRP4 expression shows unfavorable associations in BRCA, KIRP, PCPG, LIHC and UCEC, but favorable associations in ESCA. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for PGLYRP4 RNA expression.
This table summarizes PGLYRP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for PGLYRP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGLYRP4 shows higher tumor expression in LUSC, LUAD, HNSC, BLCA, BRCA and COAD. The LUSC box plot shows higher PGLYRP4 RNA expression in tumor versus normal tissue (log2 FC = +2.544, t-test p < 0.001).
This table shows molecular features associated with PGLYRP4 in patient tissues and cancer cell lines. In patient samples, PGLYRP4 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, PGLYRP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
